Gasior M, Swiader M, Przybyłko M, Borowicz K, Turski W A, Kleinrok Z, Czuczwar S J
Department of Pharmacology, Medical University School, Lublin, Poland.
Eur J Pharmacol. 1998 Jul 10;352(2-3):207-14. doi: 10.1016/s0014-2999(98)00375-6.
The aim of this study was to determine the interaction potential of the new antiepileptic drug felbamate (2-phenyl-1,3-propanediol dicarbamate) with three Ca2+ channel blockers (nicardipine, nifedipine, and flunarizine), one Ca2+ channel activator (Bay K 8644; 1,4-dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)-phenyl]-3-pyridi ne carboxylic acid), and two methylxanthines (caffeine and aminophylline (theophylline2 . ethylenediamine)) which are all known to markedly change protective effects of conventional antiepileptic drugs. To do so, the maximal electroshock seizure test in mice (an experimental model predicting drug efficacy in the treatment of human generalized tonic-clonic seizures) was employed to (1) quantify changes in the protective efficacy and potency of felbamate produced by adjunct drugs and (2) assess the ability of aminophylline and caffeine to affect protective efficacy afforded by a submaximal protective dose of felbamate against maximal electroshock-induced seizures. Doses of adjunct drugs were selected based on their effects on the threshold for electroconvulsions and on appropriate literature. Nicardipine (10-30 mg/kg), nifedipine (5-20 mg/kg), flunarizine (2.5-10 mg/kg), Bay K 8644 (2.5-5 mg/kg), and aminophylline (50-75 mg/kg) did not change the protective efficacy and potency of felbamate against maximal electroshock-induced tonic convulsions. Aminophylline in the dose of 100 mg/kg, however, diminished the protective potency of felbamate as evidenced by a statistically significant increase in the protective ED50 value of felbamate (a dose, in mg/kg, predicted to protect 50% of mice against convulsive stimulus) from 79.6 to 118 mg/kg; P < 0.05). Aminophylline and caffeine only at high doses (100 and 161.7 mg/kg, respectively) significantly diminished the protective efficacy of felbamate (110 mg/kg) from 96% to 27% and 40% (P < 0.05), respectively. In conclusion, felbamate shows low interaction potential with Ca2+ channel modulators and methylxanthines. Such low interaction potential clearly differentiates felbamate from conventional antiepileptic drugs where protective effects are readily altered by the compounds tested in the present study.
本研究的目的是确定新型抗癫痫药物非氨酯(2-苯基-1,3-丙二醇二氨基甲酸酯)与三种钙通道阻滞剂(尼卡地平、硝苯地平、氟桂利嗪)、一种钙通道激活剂(Bay K 8644;1,4-二氢-2,6-二甲基-5-硝基-4-[2-(三氟甲基)-苯基]-3-吡啶甲酸)以及两种甲基黄嘌呤(咖啡因和氨茶碱(茶碱2.乙二胺))之间的相互作用可能性,所有这些药物均已知会显著改变传统抗癫痫药物的保护作用。为此,采用小鼠最大电休克惊厥试验(一种预测药物治疗人类全身性强直阵挛性惊厥疗效的实验模型)来(1)量化辅助药物对非氨酯保护效力和效能的影响,以及(2)评估氨茶碱和咖啡因影响非氨酯亚最大保护剂量对最大电休克诱发惊厥的保护效力的能力。辅助药物的剂量根据它们对惊厥阈值的影响和适当的文献来选择。尼卡地平(10 - 30 mg/kg)、硝苯地平(5 - 20 mg/kg)、氟桂利嗪(2.5 - 10 mg/kg)、Bay K 8644(2.5 - 5 mg/kg)和氨茶碱(50 - 75 mg/kg)均未改变非氨酯对最大电休克诱发强直惊厥的保护效力和效能。然而,100 mg/kg剂量的氨茶碱降低了非氨酯的保护效能,非氨酯的保护ED50值(以mg/kg为单位,预计能保护半数小鼠免受惊厥刺激的剂量)从79.6 mg/kg显著增加至118 mg/kg,证明了这一点(P < 0.05)。仅高剂量的氨茶碱(100 mg/kg)和咖啡因(161.7 mg/kg)分别显著降低了非氨酯(110 mg/kg)的保护效力,从96%降至27%和40%(P < 0.05)。总之,非氨酯与钙通道调节剂和甲基黄嘌呤的相互作用可能性较低。这种低相互作用可能性明显将非氨酯与传统抗癫痫药物区分开来,在传统抗癫痫药物中,本研究中测试的化合物很容易改变其保护作用。